Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
KN-044 |
KN-044 |
Phase 1 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours; Neoplasms |
Details
|
ONCR-177 |
ONCR-177 |
Phase 1 Clinical |
Oncorus Inc |
Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
ATOR-1015 |
ADC-1015; ATOR-1015 |
Phase 1 Clinical |
Alligator Bioscience Ab |
Solid tumours; Neoplasms |
Details
|
SAL-008 |
SAL-008 |
Phase 1 Clinical |
Xinlitai (Chengdu) Biological Technology Co Ltd |
Neoplasms |
Details
|
ADG-116 |
ADG-116 |
Phase 2 Clinical |
Adagene (Suzhou) Ltd |
Solid tumours; Neoplasms |
Details
|
BA-3071 |
CAB-CTLA-4; BA-3071 |
Phase 2 Clinical |
Beigene Ltd, Bioatla |
Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular |
Details
|
Anti-CTLA-4 monoclonal antibody (Regeneron) |
REGN-4659 |
Phase 1 Clinical |
Regeneron Pharmaceuticals Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) |
MV-049 |
Phase 1 Clinical |
Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd |
Solid tumours |
Details
|
BT-001 |
BT-001 |
Phase 2 Clinical |
Transgene Sa |
Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis |
Details
|
BAT-4706 |
BAT-4706 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Melanoma |
Details
|
RIVAL-01 |
TBio-6517; TAK-605 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd, Turnstone Biologics Inc |
Solid tumours; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Melanoma; Uterine Cervical Neoplasms |
Details
|
CD-200-AR-L |
CD-200-AR-L; hP-1-A-8 |
Phase 1 Clinical |
University Of Minnesota |
Glioblastoma |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|
Quavonlimab |
MK-1308; AK-107 |
Phase 2 Clinical |
Merck Sharp & Dohme Corp |
Solid tumours; Carcinoma, Renal Cell; Neoplasms; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
SKB-337 |
SKB337; A-337; SKB-337 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
Abatacept (Orban Biotech) |
|
Phase 2 Clinical |
Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases |
Diabetes Mellitus, Type 1 |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics Inc |
Solid tumours; Neoplasms |
Details
|
Davoceticept |
ALPN-202 |
Phase 1 Clinical |
Alpine Immune Sciences Inc |
Solid tumours; Lymphoma |
Details
|
IMM-27M |
IMM27M; IMM-27M |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Neoplasms |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Henlius) |
|
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma |
Details
|
TWP-102 |
TWP-102 |
Phase 1 Clinical |
Therawisdom Biopharma Co Ltd |
Neoplasms |
Details
|
Porustobart |
HCAb 4003-2; HBM-4003 |
Phase 2 Clinical |
|
Solid tumours; Neoplasms; Neuroendocrine Tumors; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
JS-007 |
JS-007 |
Phase 1 Clinical |
|
Solid tumours; Neoplasms; Lung Neoplasms; Melanoma |
Details
|
YH-001 |
YH-001 |
Phase 2 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd |
Solid tumours; Liver Neoplasms; Neoplasms; Sarcoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
XTX-101 |
XTX-101 |
Phase 2 Clinical |
Xilio Development Inc |
Solid tumours |
Details
|
B7-2/GM-CSF cancer gene therapy |
CIT |
Phase 1 Clinical |
Radient |
Neoplasms |
Details
|
RP-2 |
RP-2 |
Phase 1 Clinical |
Replimune, Bristol-Myers Squibb Company |
Neoplasms |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) |
|
Phase 2 Clinical |
Hualan Genetic Engineering Co Ltd |
Melanoma |
Details
|
Pembrolizumab/Quavonlimab |
MK-1308A |
Phase 3 Clinical |
Merck Sharp & Dohme Corp, Msd Ireland (Carlow) |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma |
Details
|
BMS-986288 |
BMS-986288 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Neoplasms |
Details
|
Ipilimumab biosimilar (Innovent Biologics) |
IBI-310 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
Bavunalimab |
XmAb-22841; XmAb-841 |
Phase 2 Clinical |
Xencor Inc |
Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Solid tumours; Cholangiocarcinoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck |
Details
|
Erfonrilimab |
KN-046; KN046 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd, Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Colorectal Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Thymoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms |
Details
|
TG-6050 |
TG-6050 |
Phase 1 Clinical |
Transgene Sa |
Carcinoma, Non-Small-Cell Lung |
Details
|
JK-08 |
JK-08 |
Phase 2 Clinical |
Xinlitai (Chengdu) Biological Technology Co Ltd |
Solid tumours; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis |
Details
|
Lorigerlimab |
MGD-019; AEX1344 |
Phase 2 Clinical |
Macrogenics Inc |
Liver Neoplasms; Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Neoplasm Metastasis; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Iparomlimab/Tuvonralimab |
QL-1706; PSB-205; PBS-103/PBS-105 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
SI-B003 |
SI-B003 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma |
Details
|
MEDI-5752 |
MEDI-5752 |
Phase 2 Clinical |
Medimmune Llc |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Neoplasms |
Details
|
Zalifrelimab |
AGEN-1884; RebmAb-600; UGN-301 |
Phase 2 Clinical |
4-Antibody, Ludwig Institute For Cancer Research |
Solid tumours; Hemangiosarcoma; Carcinoma; Urinary Bladder Neoplasms; Sarcoma; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BMS-986249 |
BMS-986249 |
Phase 2 Clinical |
Cytomx Therapeutics Inc |
Neoplasms |
Details
|
Botensilimab |
AGEN-1181 |
Phase 2 Clinical |
Agenus Inc |
Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Hemangiosarcoma; Neoplasms; Colonic Neoplasms; Fibrolamellar hepatocellular carcinoma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
ADG-126 |
ADG-126 |
Phase 2 Clinical |
Adagene Inc |
Solid tumours; Neoplasms |
Details
|
GI-101 |
SIM-323; SIM323; GI-101 |
Phase 2 Clinical |
GI Innovation Inc |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
KD-6001 |
KD-6001 |
Phase 2 Clinical |
Shanghai Kanda Bio-Technology Co Ltd, Shanghai Celgen Bio-Pharmaceutical Co Ltd |
Solid tumours; Neoplasms; Melanoma |
Details
|
ONC-392 |
ONC-392 |
Phase 3 Clinical |
Oncoimmune Inc |
Prostatic Neoplasms, Castration-Resistant; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Carcinoma, Adenoid Cystic; Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Cystadenocarcinoma, Serous; Anorectal disorders; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Head and Neck Neoplasms |
Details
|
CS-1002 |
SHR-8068; CS-1002 |
Phase 2 Clinical |
Cstone Pharmaceuticals |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
IDO-derived peptide vaccine/PD-L1-derived peptide vaccine |
IO-102/IO-103 |
Phase 3 Clinical |
Herlev Hospital |
Squamous Cell Carcinoma of Head and Neck; Melanoma |
Details
|
IO-102 |
IO-102 |
Phase 2 Clinical |
Herlev Hospital, Merck Sharp & Dohme Corp, Io Biotech Aps |
Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell; Mouth Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
RP-3 |
RP-3 |
Phase 2 Clinical |
|
Solid tumours; Liver Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular |
Details
|
BCD-217 |
BCD-217 |
Phase 3 Clinical |
Biocad |
Melanoma |
Details
|
Vudalimab |
XmAb-20717; XmAb-717 |
Phase 2 Clinical |
Xencor Inc |
Carcinoma, Neuroendocrine; Prostatic Neoplasms; Vulvar Neoplasms; Cholangiocarcinoma; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Astrocytoma; Carcinoma, Squamous Cell; Thymoma; Breast Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms, Castration-Resistant; Adnexal Diseases; Mesothelioma; Adenoma, Acidophil; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours |
Details
|